Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)

Publication date: Available online 30 October 2019Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Joseph Carmicheal, Asish Patel, Vipin Dalal, Pranita Atri, Amaninder S. Dhaliwal, Uwe A. Wittel, Mokenge P. Malafa, Geoffrey Talmon, Benjamin J. Swanson, Shailender Singh, Maneesh Jain, Sukhwinder Kaur, Surinder K. BatraAbstractPancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 6%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.Graphical abstract
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research